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Background: Although use of assist devices in high risk percutaneous coronary intervention (HRPCI) has increased, current Impella registries 
(USpella, Europella) did not compare HRPCI with and without support. We used historic controls from the Dynamic Registry (Dyn Reg) to evaluate the 
benefit of Impella in HRPCI.
methods: Two percent of patients (n=214) underwent HRPCI within the Dynamic Registry (Dyn HRPCI); unprotected left main PCI (ULM n=38), ≥2 
vessel PCI with ejection fraction < 30% (n=65), PCI of all 3 vessels (n=47) and ≥2 vessel PCI with rotational atherectomy (n=64). Baseline traits and 
outcomes were compared to the overall Dyn Reg, USpella and Europella.
results: One-year mortality (14.7% vs 4.6%, p<0.001) and major adverse cardiac events (33.2% vs 21.5%, p<0.001) were higher in Dyn HRPCI 
than Dyn Reg. Compared to Dyn HRPCI, Europella (n=144) and USpella (n=175) patients were older (66±13 vs 72±10 and 70±10, p<0.001), 
had more renal insufficiency (14% vs 29% and 33%, p<0.001) and were more likely to have had a previous myocardial infarction (MI) (37% vs 
53% and 56%, p≤0.002). Europella and USpella patients had lower ejection fraction (26±6 and 31±17 vs 40±17, p<0.001), but less multivessel 
disease (82% and 89% vs 100%, p<0.001). ULM PCI was performed more frequently (53% and 51% vs 18%, p <0.001). In-hospital mortality was 
similar in USpella and Dyn HRPCI (3% vs 6%, p=0.34), but less patients in USpella sustained periprocedural MI (1% vs 6%, p=0.03) or required 
repeat revascularization (0% vs 3%, p=0.02). Bleeding requiring transfusion was higher in USpella vs. Dyn HRPCI (10% vs 4%, p=0.02). There was no 
difference in 30-day mortality between Europella and USpella vs. Dyn HRPCI, (6% and 4% vs 7%, p=0.70 and 0.27). There was a lower incidence of 
MI in Europella and USpella vs. Dyn HRPCI (0% and 1% vs 6%, p=0.002 and 0.03) and less repeat revascularization (0.6% in USpella vs 5% in Dyn 
HRPCI, p=0.015) at 30 days.
conclusions: Although PCI-related mortality was unchanged, MI and repeat revascularization were reduced with use of Impella, despite the 
challenges of intervening on sicker patients. These data support the use of Impella in high risk PCI, with the trade-off of a small increase in 
significant bleeding.
